SUWON, South Korea–(BUSINESS WIRE)–OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a number one developer of RNAi therapeutics, right now introduced the publication of preclinical analysis on the androgenetic alopecia (hair loss) therapy program, OLX104C, in Molecular Pharmaceutics.
The Company is growing the therapy for androgenetic alopecia based mostly on cell-penetrating uneven siRNA (cp-asiRNA) platform know-how. OLX104C reduces the expression of androgen receptor (AR), one of many key elements that trigger androgenetic alopecia, which leads to the suppression of the hair cycle transition from anagen to telogen part.
The paper “Efficacy of Asymmetric siRNA Targeting Androgen Receptor for the Treatment of Androgenetic Alopecia” is predicated on the preclinical examine on OLX104C, collectively performed by OliX and the analysis staff of Ik Jun Moon, M.D., Ph.D. & Chong-hyun Won, M.D., Ph.D. of University of Ulsan College of Medicine, Asan Medical Center. The analysis staff demonstrated the efficacy of AR discount, hair loss inhibition, and lengthy length of motion in main cultured human follicle dermal papilla cells (HFDPC) and rodent fashions of hair loss.
Dong Ki Lee, Ph.D., Founder and Chief Executive Officer of OliX mentioned, “We are glad that, via this publication of our examine in Molecular Pharmaceutics, the wonderful efficacy of our cp-asiRNA focusing on AR on hair loss has been verified by peer reviewers. We plan to submit a Human Research Ethics Application (HREA) for Phase 1 medical trial close to the top of this yr, and we count on profitable medical outcomes.”
About OliX Pharmaceuticals
OliX Pharmaceuticals is a clinical-stage pharmaceutical firm growing therapeutics towards a wide range of problems by down-regulating the expression of disease-causing genes based mostly by itself proprietary RNAi know-how.
Learn extra: https://www.olixpharma.com/eng